Similarly, in the above-mentioned study by Del Re et al. the PFS after receiving second-line osimertinib was significantly shorter in patients with high AF of the sensitizing EGFR-mutant in their cfDNA than in patients with low AF [269]. The gene discussed is EGFR; the disease is atrial fibrillation.